Collectively, the entities operate 26 primary care centers in Florida, serving roughly 35,000 patients, and employing more than 800 workers.
According to the filing, the “most significant headwind” was related to the Medicare risk-adjustment model implemented by the Centers for Medicare & Medicaid Services (CMS), a federal agency within the U.S. Department of Health and Human Services.
The firms earn revenue through their contracts with health plans. In January this year, the CMS overhauled the way medical conditions are reimbursed within Medicare plans. The changes negatively affected the entities’ revenues, with the firms projecting a decline of around 12 percent by 2026, the filing said.
Another regulatory change that had a negative impact was Medicaid, from which the entities used to gain around $100 million in revenues yearly.
In the aftermath of the COVID-19 pandemic, the number of people seeking Medicaid assistance increased. The redetermination of Medicaid eligibility was paused for three years to ensure Americans did not lose out on health coverage during the pandemic.
This pause in predetermining eligibility ended in April last year. Since then, more than 25 million people across the country disenrolled from Medicaid by September this year. As a result of these disenrollments and redeterminations, the entities saw a more than 50 percent year-over-year decline in Medicaid revenue and patients as of July.
The businesses have also struggled from rising medical expenses post the pandemic, decrease in valuations, and high debt and interest burdens, Campbell said. MBMG tried to sell its assets, eventually deciding on the proposed sale to Conviva.
The companies have roughly $6.9 million in unrestricted cash and cash equivalents. Without any funding, the firms will not be able to meet their costs, the filing said. The businesses have a liability of approximately $479 million.
A prominent doctor and trans rights advocate admitted she deliberately withheld publication of a $10 million taxpayer-funded study on the effect of puberty blockers on American children — after finding no evidence that they improve patients’ mental health.
Dr. Johanna Olson-Kennedy told the New York Times that she believes the study would be “weaponized” by critics of transgender care for kids, and that the research could one day be used in court to argue “we shouldn’t use blockers.”
Critics – including one of Olson-Kennedy’s fellow researchers on the study — said the decision flies in the face of research standards and deprives the public of “really important” science in a field where Americans remain firmly divided.
End goal. Psychotropic drugs for all. Zombie Nation, USA. Keep gassing the masses until they don't know which end is up!
I'm a fan of that industrial solvent the author mentions, too. It's DMSO. Many health benefits. But use with caution, a little goes a long way.
That's why I don't use Facebook.
Or TikTok, don’t allow either on my phone.
World Bank bureaucrats lost track of at least $24B in funds fighting climate change: ‘Could be twice or 10 times more’
https://nypost.com/2024/10/23/business/world-bank-bureaucrats-lost-track-of-at-least-24b-in-funds-fighting-climate-change-report/
An investigation by the left-leaning NGO Oxfam ripped the DC-based international lender’s “poor record-keeping practices.”
Health Care Network Serving 35,000 Patients Files for Bankruptcy
https://www.theepochtimes.com/health/healthcare-network-serving-35000-patients-files-for-bankruptcy-5742916
Collectively, the entities operate 26 primary care centers in Florida, serving roughly 35,000 patients, and employing more than 800 workers.
According to the filing, the “most significant headwind” was related to the Medicare risk-adjustment model implemented by the Centers for Medicare & Medicaid Services (CMS), a federal agency within the U.S. Department of Health and Human Services.
The firms earn revenue through their contracts with health plans. In January this year, the CMS overhauled the way medical conditions are reimbursed within Medicare plans. The changes negatively affected the entities’ revenues, with the firms projecting a decline of around 12 percent by 2026, the filing said.
Another regulatory change that had a negative impact was Medicaid, from which the entities used to gain around $100 million in revenues yearly.
In the aftermath of the COVID-19 pandemic, the number of people seeking Medicaid assistance increased. The redetermination of Medicaid eligibility was paused for three years to ensure Americans did not lose out on health coverage during the pandemic.
This pause in predetermining eligibility ended in April last year. Since then, more than 25 million people across the country disenrolled from Medicaid by September this year. As a result of these disenrollments and redeterminations, the entities saw a more than 50 percent year-over-year decline in Medicaid revenue and patients as of July.
The businesses have also struggled from rising medical expenses post the pandemic, decrease in valuations, and high debt and interest burdens, Campbell said. MBMG tried to sell its assets, eventually deciding on the proposed sale to Conviva.
The companies have roughly $6.9 million in unrestricted cash and cash equivalents. Without any funding, the firms will not be able to meet their costs, the filing said. The businesses have a liability of approximately $479 million.
Hits both subjects.
Woke doc refused to publish $10 million trans kids study that showed puberty blockers didn’t help mental health
https://nypost.com/2024/10/23/us-news/doctor-refused-to-publish-trans-kids-study-that-showed-puberty-blockers-didnt-help-mental-health/
A prominent doctor and trans rights advocate admitted she deliberately withheld publication of a $10 million taxpayer-funded study on the effect of puberty blockers on American children — after finding no evidence that they improve patients’ mental health.
Dr. Johanna Olson-Kennedy told the New York Times that she believes the study would be “weaponized” by critics of transgender care for kids, and that the research could one day be used in court to argue “we shouldn’t use blockers.”
Critics – including one of Olson-Kennedy’s fellow researchers on the study — said the decision flies in the face of research standards and deprives the public of “really important” science in a field where Americans remain firmly divided.